Torrent Pharmaceuticals

Indicators

3 bullish · 5 neutral · 13 bearish

Verdict

Torrent Pharma shows steady revenue growth and expanding margins, driven by strong India performance and a healthy international pipeline.

Why

• •Consolidated revenue grows from ₹3,178 Cr in Q1 FY26 to ₹4,921 Cr in Q1 FY27, with India contributing the largest share at ₹2,890 Cr.
• •Profitability strengthens as operating EBITDA margin rises from 32.3% to 33.8%, supported by stable gross margins around 76%.
• •International markets show steady recovery after Q3 FY26 peaks, with Brazil and US revenues normalizing to sustainable levels.
• •The JB Business segment delivers strong returns with a 35.3% EBITDA margin on ₹1,201 Cr revenue in Q1 FY27.

Signals